Earnings Feed
Start Free
Home/Filings/4/0001012975-25-000680
4//SEC Filing

CRANDELL KEITH 4

Accession 0001012975-25-000680

CIK 0001885522other
View on SEC.govCompany Profile

Filed

Oct 28, 8:00 PM ET

Accepted

Oct 29, 7:21 PM ET

Size

21.3 KB

Accession

0001012975-25-000680

Insider Transaction Report

Form 4
Period: 2025-10-27
Neumora Therapeutics, Inc.NMRA
ARCH Venture Partners XII, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-27$2.61/sh+1,915,700$4,999,977→ 6,046,907 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    11,886,758

  • Common Stock

    (indirect: By ARCH Venture Fund VIII Overage, L.P.)
    2,321,566

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    12,205,379

  • Common Stock

    (indirect: By ARCH Venture Fund VII, L.P.)
    1,387,228
ARCH Venture Partners XII, LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-27$2.61/sh+1,915,700$4,999,977→ 6,046,907 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund VIII Overage, L.P.)
    2,321,566

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    11,886,758

  • Common Stock

    (indirect: By ARCH Venture Fund VII, L.P.)
    1,387,228

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    12,205,379
CRANDELL KEITH
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-27$2.61/sh+1,915,700$4,999,977→ 6,046,907 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    12,205,379

  • Common Stock

    (indirect: By ARCH Venture Fund VIII Overage, L.P.)
    2,321,566

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    11,886,758

  • Common Stock

    (indirect: By ARCH Venture Fund VII, L.P.)
    1,387,228
GILLIS STEVEN
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-27$2.61/sh+1,915,700$4,999,977→ 6,046,907 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund VIII Overage, L.P.)
    2,321,566

  • Common Stock

    (indirect: By ARCH Venture Fund VII, L.P.)
    1,387,228

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    12,205,379

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    11,886,758
NELSEN ROBERT
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-27$2.61/sh+1,915,700$4,999,977→ 6,046,907 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund VIII Overage, L.P.)
    2,321,566

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    12,205,379

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    11,886,758

  • Common Stock

    (indirect: By ARCH Venture Fund VII, L.P.)
    1,387,228
BYBEE CLINTON
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-27$2.61/sh+1,915,700$4,999,977→ 6,046,907 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    12,205,379

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    11,886,758

  • Common Stock

    (indirect: By ARCH Venture Fund VII, L.P.)
    1,387,228

  • Common Stock

    (indirect: By ARCH Venture Fund VIII Overage, L.P.)
    2,321,566
ARCH Venture Fund XII, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-27$2.61/sh+1,915,700$4,999,977→ 6,046,907 total(indirect: By ARCH Venture Fund XII, L.P.)
Holdings

  • Common Stock

    (indirect: By ARCH Venture Fund VII, L.P.)
    1,387,228

  • Common Stock

    (indirect: By ARCH Venture Fund X, L.P.)
    12,205,379

  • Common Stock

    (indirect: By ARCH Venture Fund VIII Overage, L.P.)
    2,321,566

  • Common Stock

    (indirect: By ARCH Venture Fund X Overage, L.P.)
    11,886,758
Footnotes (6)
  • [F1]Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
  • [F2]Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
  • [F3]Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
  • [F4]Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
  • [F5]Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
  • [F6]ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.

Documents

1 file

Issuer

Neumora Therapeutics, Inc.

CIK 0001885522

→
Entity typeother

Related Parties

1
  • filerCIK 0001219039

Filing Metadata

Form type
4
Filed
Oct 28, 8:00 PM ET
Accepted
Oct 29, 7:21 PM ET
Size
21.3 KB
View on SEC.gov